Skip to main content
. 2022 Jun 14;53(10):4614–4626. doi: 10.1017/S0033291722001520

Table 2.

Baseline-adjusted pairwise comparisons between CBM-pa group and control group at each time point (T1: post-intervention, T2: 1-month and T3: 3-month follow-up)

Measure Time Mean difference (95% CI) z p %
Interpretation bias
Similarity Rating Task Target: bias T1 −0.24 (−0.55 to 0.06) −1.55 0.120
T2 −0.29 (−0.61 to 0.02) −1.82 0.069
T3 −0.39 (−0.70 to −0.08) −2.43 0.014
Similarity Rating Task Foil: bias T1 −0.10 (−0.30 to 0.11) −0.96 0.339
T2 −0.11 (−0.32 to 0.10) −1.04 0.298
T3 −0.09 (−0.29 to 0.12) −0.84 0.399
Scrambled Sentences Task: paranoid bias T1 −13.11 (−27.99 to 1.77) −1.73 0.084
Scrambled Sentences Task: non-paranoid bias T1 24.13 (11.30–36.95) 3.69 0.000
Cognitive flexibility T1 0.58 (−6.50 to 7.67) 0.16 0.872 1.2%
Clinical outcomes
PANSS: item 6 T1 −0.11 (−0.76 to 0.54) −0.33 0.740 −2.1%
T2 −0.20 (−0.86 to 0.45) −0.60 0.547 −3.9%
T3 −0.43 (−1.08 to 0.22) −1.31 0.191 −8.4%
Paranoia Scale T1 −4.03 (−10.52 to 2.47) −1.22 0.224 −6.4%
T2 −6.72 (−13.29 to −0.15) −2.01 0.045 −10.7%
T3 −3.37 (−9.80 to 3.06) −1.03 0.304 −5.4%
Paranoid Thoughts Scale: total T1 −7.95 (−22.80 to 6.89) −1.05 0.294 −8.9%
T2 −9.02 (−23.97 to 5.94) −1.18 0.237 −10.1%
T3 −3.04 (−17.63 to 11.53) −0.41 0.683 −3.4%
Peters Delusions Inventory T1 0.60 (−1.55 to 2.74) 0.54 0.587 6.2%
T3 −0.80 (−3.11 to 1.52) −0.68 0.500 −8.3%
HADS: total score T1 −2.03 (−4.79 to 0.72) −1.45 0.148 −28.9%
T2 −1.12 (−3.91 to 1.66) −0.79 0.429 −16.0%
T3 −0.18 (−2.96 to 2.60) −0.13 0.900 −2.5%
Stress/distress
VRE pre–post change: sadness T1 −4.30 (−15.30 to 6.70) −0.77 0.443
VRE pre–post change: paranoia T1 −1.77 (−14.13 to 10.60) −0.28 0.779
VRE pre–post change: friendly T1 −0.04 (−0.17 to 0.09) −0.63 0.527
VRE pre–post change: anxiety T1 0.26 (−13.87 to 14.39) 0.04 0.971
VRE SSPS T1 0.06 (−0.50 to 0.63) 0.21 0.830

HADS, Hospital Anxiety and Depression Scale; PANSS, Positive and Negative Symptom Scale; SSPS, State Social Paranoia Scale; VRE, virtual reality environment.

A positive value of mean difference means that the participants of the CBM-pa group score higher than the participants of the control group. For clinical outcomes, the change of percentages from mean at baseline is provided.